What is the address of DR. L. SCHAUVLIEGE - HEMATOLOOG?

The registered office of DR. L. SCHAUVLIEGE - HEMATOLOOG is located at Drongenstationstraat 6, 9031 Gent.

Is DR. L. SCHAUVLIEGE - HEMATOLOOG still active?

Yes. According to the CBE (2 November 2026) DR. L. SCHAUVLIEGE - HEMATOLOOG is active, legal situation “Normale toestand”, started on 11 July 2006.

Is DR. L. SCHAUVLIEGE - HEMATOLOOG registered on Peppol?

Yes, DR. L. SCHAUVLIEGE - HEMATOLOOG is registered on the Peppol network with ID 0208:0882550936.

What is the enterprise number of DR. L. SCHAUVLIEGE - HEMATOLOOG?

The enterprise number of DR. L. SCHAUVLIEGE - HEMATOLOOG is BE0882550936.

When was DR. L. SCHAUVLIEGE - HEMATOLOOG founded?

DR. L. SCHAUVLIEGE - HEMATOLOOG was founded on 11 July 2006.

Who are the directors of DR. L. SCHAUVLIEGE - HEMATOLOOG?

According to the 2025 annual accounts, the directors of DR. L. SCHAUVLIEGE - HEMATOLOOG are: Liesbeth SCHAUVLIEGE, Jo VAN PARYS.

Is DR. L. SCHAUVLIEGE - HEMATOLOOG a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 11 July 2006; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account; 2 establishments in the CBE; 1 events from the Belgian Official Gazette processed.

How much profit did DR. L. SCHAUVLIEGE - HEMATOLOOG make in 2025?

DR. L. SCHAUVLIEGE - HEMATOLOOG posted a profit after taxes of € 428,214 in financial year 2025.

What is the revenue of DR. L. SCHAUVLIEGE - HEMATOLOOG?

As a small company, DR. L. SCHAUVLIEGE - HEMATOLOOG is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 608,635.

DR. L. SCHAUVLIEGE - HEMATOLOOG (Private Limited) - Gent

Dossier DR. L. SCHAUVLIEGE - HEMATOLOOG, printed on 3 November 2026 from databakkes.be/en/0882550936/dr-l-schauvliege-hematoloog. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

DR. L. SCHAUVLIEGE - HEMATOLOOG from Gent, company number BE0882550936, closed financial year 2025 with a result of € 428,214 after tax. For that financial year DR. L. SCHAUVLIEGE - HEMATOLOOG recorded a gross margin of € 608,635 and equity of € 1.5 million. Compared with financial year 2024, the result moved from € 283,275 to € 428,214. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.

What it is worth Growing

€ 1.5 million

▲ 28% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 428,214

▲ 51% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 165,656

▲ 10% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 113,765 paid out

27 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Vehicles and equipment

€ 21,028

▼ 41% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 4,122

▼ 80% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 3,738

▲ 230% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 78,660

▲ 79% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 269,711 Gross margin 2022: € 269,711 First fiscal year in the series	€ 333,865 Gross margin 2023: € 333,865 ▲ 24% vs 2022 (€ 269,711) Favourable step	€ 463,422 Gross margin 2024: € 463,422 ▲ 39% vs 2023 (€ 333,865) Favourable step	€ 608,635 Gross margin 2025: € 608,635 ▲ 31% vs 2024 (€ 463,422) Favourable step	▲ 31%
Profit after taxes	€ 127,653 Profit after taxes 2022: € 127,653 First fiscal year in the series	€ 226,785 Profit after taxes 2023: € 226,785 ▲ 78% vs 2022 (€ 127,653) Favourable step	€ 283,275 Profit after taxes 2024: € 283,275 ▲ 25% vs 2023 (€ 226,785) Favourable step	€ 428,214 Profit after taxes 2025: € 428,214 ▲ 51% vs 2024 (€ 283,275) Favourable step	▲ 51%
Equity	€ 778,385 Equity 2022: € 778,385 First fiscal year in the series	€ 945,300 Equity 2023: € 945,300 ▲ 21% vs 2022 (€ 778,385) Favourable step	€ 1,135,769 Equity 2024: € 1,135,769 ▲ 20% vs 2023 (€ 945,300) Favourable step	€ 1,450,218 Equity 2025: € 1,450,218 ▲ 28% vs 2024 (€ 1,135,769) Favourable step	▲ 28%
Total debts	€ 152,827 Total debts 2022: € 152,827 First fiscal year in the series	€ 100,037 Total debts 2023: € 100,037 ▼ 35% vs 2022 (€ 152,827) Favourable step	€ 72,970 Total debts 2024: € 72,970 ▼ 27% vs 2023 (€ 100,037) Favourable step	€ 104,518 Total debts 2025: € 104,518 ▲ 43% vs 2024 (€ 72,970) Unfavourable step	▲ 43%
Cash	€ 86,525 Cash 2022: € 86,525 First fiscal year in the series	€ 64,858 Cash 2023: € 64,858 ▼ 25% vs 2022 (€ 86,525) Unfavourable step	€ 150,786 Cash 2024: € 150,786 ▲ 132% vs 2023 (€ 64,858) Favourable step	€ 165,656 Cash 2025: € 165,656 ▲ 10% vs 2024 (€ 150,786) Favourable step	▲ 10%
Land & buildings	€ 175,846 Land & buildings 2022: € 175,846 First fiscal year in the series	€ 157,781 Land & buildings 2023: € 157,781 ▼ 10% vs 2022 (€ 175,846) Unchanged	€ 139,716 Land & buildings 2024: € 139,716 ▼ 11% vs 2023 (€ 157,781) Unchanged	€ 122,353 Land & buildings 2025: € 122,353 ▼ 12% vs 2024 (€ 139,716) Unchanged	▼ 12%
Retained profit	€ 765,985 Retained profit 2022: € 765,985 First fiscal year in the series	€ 932,900 Retained profit 2023: € 932,900 ▲ 22% vs 2022 (€ 765,985) Favourable step	€ 1,123,369 Retained profit 2024: € 1,123,369 ▲ 20% vs 2023 (€ 932,900) Favourable step	€ 1,437,818 Retained profit 2025: € 1,437,818 ▲ 28% vs 2024 (€ 1,123,369) Favourable step	▲ 28%
Dividend	€ 115,880 Dividend 2022: € 115,880 First fiscal year in the series	€ 59,870 Dividend 2023: € 59,870 ▼ 48% vs 2022 (€ 115,880) Unchanged	€ 92,806 Dividend 2024: € 92,806 ▲ 55% vs 2023 (€ 59,870) Unchanged	€ 113,765 Dividend 2025: € 113,765 ▲ 23% vs 2024 (€ 92,806) Unchanged	▲ 23%
Bank debt	€ 117,457 Bank debt 2022: € 117,457 First fiscal year in the series	€ 70,140 Bank debt 2023: € 70,140 ▼ 40% vs 2022 (€ 117,457) Favourable step	€ 20,547 Bank debt 2024: € 20,547 ▼ 71% vs 2023 (€ 70,140) Favourable step	€ 4,122 Bank debt 2025: € 4,122 ▼ 80% vs 2024 (€ 20,547) Favourable step	▼ 80%
Balance sheet total	€ 931,213 Balance sheet total 2022: € 931,213 First fiscal year in the series	€ 1,045,337 Balance sheet total 2023: € 1,045,337 ▲ 12% vs 2022 (€ 931,213) Unchanged	€ 1,208,739 Balance sheet total 2024: € 1,208,739 ▲ 16% vs 2023 (€ 1,045,337) Unchanged	€ 1,554,735 Balance sheet total 2025: € 1,554,735 ▲ 29% vs 2024 (€ 1,208,739) Unchanged	▲ 29%

Key figures of DR. L. SCHAUVLIEGE - HEMATOLOOG, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to DR. L. SCHAUVLIEGE - HEMATOLOOG?

What happened at DR. L. SCHAUVLIEGE - HEMATOLOOG in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2029 Jo VAN PARYS stepped down as director. NBB
Aug 31, 2026 New annual accounts for financial year 2025: profit of € 428,214 (▲ 51% vs 2024). filed late Source: NBB ↗
2023 Liesbeth SCHAUVLIEGE became a director. NBB
2023 Jo VAN PARYS became a director. NBB
Jul 26, 2006 Incorporation, published in the Gazette. Source: Staatsblad ↗
Jul 14, 2006 New establishment in Roeselare. KBO
Jul 14, 2006 New establishment in Izegem. KBO

In short

From € 127,653 profit in 2022 to € 428,214 profit in 2025.

Paid € 515,426 in corporate taxes since 2022.

Best year ever: 2025, with € 428,214 profit.

Paid out € 382,322 in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Liesbeth SCHAUVLIEGE

DR. L. SCHAUVLIEGE - HEMATOLOOG

Behind DR. L. SCHAUVLIEGE - HEMATOLOOG is Liesbeth SCHAUVLIEGE.

Directors

According to the 2025 annual accounts

Liesbeth SCHAUVLIEGE

Director

since 2023

Jo VAN PARYS

Director

since 2023 · until 2029

Establishments

Establishment units

Physical locations of this company

Registered office

Drongenstationstraat 6

9031 Gent

2.254.814.587

Wilgenstraat 2

8800 Roeselare

Active since 14 July 2006

2.254.815.676

Ommegangstraat 7

8870 Izegem

Active since 14 July 2006

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Shareholders according to the Official Gazette deeds

Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.

Incorporation

26 July 2006 Source: Deed ↗

Liesbeth Camilla SCHAUVLIEGE(oprichter) 100%

Details

Company number: 0882.550.936
VAT number: BE 0882.550.936
Registered office: Drongenstationstraat 6, 9031 Gent
Names & denominations: DR. L. SCHAUVLIEGE - HEMATOLOOG
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 11 July 2006
Peppol: Active · Active since 31 Mar 2026

View on CBE Public ↗ Annual accounts (NBB) ↗